Singapore, Singapore, March 3rd, 2026, FinanceWire
Merifund Capital Management Pte. Ltd. has provided commentary on the recent Nasdaq Global Select Market listing of Generate Biomedicines, noting the company’s implied valuation of approximately $2.2 billion and the broader implications for the biotechnology sector.
Generate Biomedicines priced 25 million shares at $16.20 per share, resulting in gross proceeds of approximately $405.5 million before fees. Underwriters hold a 30-day option to purchase up to an additional 3.8 million shares. The shares are trading under the ticker GENB, with closing of the transaction subject to customary conditions.
According to public disclosures, proceeds are expected to be directed primarily toward advancing GB-0895, an engineered anti-TSLP antibody, into Phase 3 trials for severe asthma. The planned studies include a 52-week treatment window with dosing administered twice annually. In previously reported Phase 1 data involving 96 patients, the candidate demonstrated an extended half-life of approximately 89 days, with biomarker suppression observed for at least six months. Binding assays disclosed for the development program indicate femtomolar-range affinity.
Generate Biomedicines describes its platform as an industrialized approach to protein design, supported by a data library comprising approximately 160,000 protein structures and 190 million genetic sequences. The company has disclosed approximately $668 million in equity financing since emerging from stealth, including $260.5 million raised in its most recent Series C round.
Anthony Saunders, Director of Private Equity at Merifund Capital Management Pte. Ltd., stated that public market participants continue to assess platform-based biotechnology companies based on the relationship between discovery capabilities, clinical execution, and capital efficiency. He noted that investors are closely monitoring the progression from algorithm-driven design to clinical endpoints, particularly in late-stage trials.
Partnership activity provides an additional reference point. Generate Biomedicines reported $111.6 million in collaboration revenue in its most recent full-year accounts, alongside a net loss of $226.3 million. Under disclosed terms, its collaboration with Novartis includes $62 million in upfront consideration, of which $14.3 million is in equity, and outlines potential milestone payments exceeding $950 million plus tiered royalties. The Amgen collaboration begins with $47.7 million upfront and references a potential program value of approximately $1.8 billion over the term of the agreement.
Merifund noted that partnership structures can serve both as non-dilutive funding sources and as validation mechanisms, while emphasizing that clinical outcomes remain central to long-term value realization.
The listing occurs amid a gradual reopening of the biotechnology IPO market. Recent offerings have brought sector fundraising to approximately $1.4 billion this month, compared with approximately $928.1 million over the same period a year earlier. At the same time, public biotechnology indices remain significantly below prior-cycle peaks, maintaining focus on capital allocation, trial design, and operational timelines.
Looking ahead, the SOLAIRIA Phase 3 program for GB-0895 is expected to complete enrolment within the next two to three years. Additional pipeline programs include early-stage constructs such as a monoclonal antibody designed to bind circulating payload released from antibody-drug conjugates and an armored CAR T therapy candidate in ovarian cancer.
Merifund Capital Management stated that it will continue to monitor developments in platform-based biotechnology, including the relationship between clinical progress, partnership economics, and capital deployment.
About Merifund Capital Management
Founded in 2010, Merifund Capital Management Pte. Ltd. (UEN: 201024554E) is a Singapore-headquartered hedge fund manager that runs traditional long-only portfolios alongside long/short equity, global macro, event-driven and systematic strategies. The firm uses derivatives selectively to manage exposures and pursue opportunities, with capital preservation, liquidity and disciplined risk controls at the centre of its process. ESG factors are incorporated within the investment framework in line with recognised global sustainability standards. Merifund serves accredited investors, family offices, foundations and endowments, and is expanding its suite of offerings for a wider retail audience. Insights are published at https://merifund.com/insights and media enquiries can be directed to Tao Yang at media@merifund.com, with further information available at https://merifund.com.
Website: https://merifund.com